Ekso Bionics Holdings, Inc. — Q2 2021 Form 10-Q
The filing is for the quarter and six months ended June 30, 2021. The registrant is Ekso Bionics Holdings, Inc. (Nasdaq: EKSO); this differs from the company name in the request metadata. The company develops and sells medical and industrial exoskeleton products. Unless noted otherwise, amounts below are in millions of U.S. dollars; the filing presents financial statements in thousands.
Financial performance
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $2.211 | $2.264 | $4.121 | $3.731 |
| Gross profit / margin | $1.292 / 58% | $1.259 / 56% | $2.527 / 61% | $1.896 / 51% |
| Operating expenses | $4.640 | $4.351 | $9.014 | $9.769 |
| Operating loss | $(3.348) | $(3.092) | $(6.487) | $(7.873) |
| Net loss | $(1.273) | $(11.767) | $(4.943) | $(14.301) |
| Basic loss per share | $(0.10) | $(1.88) | $(0.42) | $(2.37) |
Q2 revenue declined 2% year over year, while first-half revenue increased 10%. First-half gross margin improved to 61% from 51%, attributed to higher medical-device sales, lower EksoWorks production costs for the EVO Vest, and a lower share of lower-margin collaborative arrangements. Despite lower first-half operating expenses, the company remained loss-making. Reported net loss benefited from a $1.1 million PPP loan-forgiveness gain and a $0.9 million warrant revaluation gain in the first half; warrant revaluation is non-cash and sensitive to the share price.
Cash, debt and liquidity
- Cash at June 30 was $45.938 million, versus $12.862 million at December 31, 2020. Cash from operations was negative $5.606 million for the first half; financing provided $38.712 million.
- Working capital was $46.6 million, compared with $13.4 million at year-end 2020. The company reported approximately $43.9 million of unrestricted cash after the $2.0 million minimum-cash covenant amount.
- Notes payable, net, were $1.991 million, representing the Pacific Western Bank term loan, due in 2023. The company reported compliance with its liquidity and other loan covenants. Total liabilities were $12.877 million; warrant liabilities were $4.626 million.
- Management stated that available unrestricted cash was sufficient to fund operations beyond one year from issuance of the financial statements. The company has a substantial accumulated deficit of $204.046 million and a history of operating losses and negative operating cash flow.
Material changes and business developments
- In February 2021, the company raised $36.5 million net through a common-stock offering; it also received $0.7 million net from its ATM program and $1.4 million from warrant exercises in the first half. Shares outstanding rose from 8.349 million at year-end to 12.655 million at June 30, creating meaningful dilution.
- The SBA approved full forgiveness of the $1.086 million PPP loan and accrued interest, totaling $1.099 million; the company recorded the amount as a gain and has no remaining obligation for that loan.
- Management reported booking 20 EksoNR units in Q2, including 11 new subscription units, and highlighted an expanded Kindred Healthcare partnership. The company is shifting from rentals toward subscriptions, which generally defer recognition of revenue over contract terms.
- By segment, Q2 EksoHealth revenue was $1.862 million and EksoWorks revenue was $0.349 million. For the first half, the respective amounts were $3.589 million and $0.532 million.
Outlook, risks and contingencies
The filing gives no quantified revenue, earnings, or cash-flow guidance. Management described expectations for more in-person customer engagement as vaccination and onsite activity resumed, but said COVID-19 uncertainty makes the business impact difficult to project. The company cited risks including customer adoption and long, variable sales cycles; regulatory approvals and reimbursement; competition and product development; financing needs; and COVID-19 effects. It specifically warned that shortages and longer lead times for semiconductors, batteries, metals, plastics, and manufacturing services could affect results, while stating it believed semiconductor supplies were adequate for most of 2021. Management reported no pending legal proceedings expected to have a material adverse effect. Purchase obligations were $1.267 million, expected within one year; other contractual commitments include loan payments and facility leases.
Key investor verification points
- Confirm the pace and economics of EksoNR subscriptions, renewal rates, backlog conversion, and the revenue-recognition timing associated with the shift away from rentals.
- Assess whether improved gross margins and lower operating cash use can persist as product volumes and development spending change.
- Track cash burn against management’s stated runway, the $2.0 million cash covenant, and the 2023 term-loan maturity.
- Evaluate dilution and potential share issuance from outstanding warrants, including their liability classification and possible cash-payment provisions.
- Monitor supply-chain availability, COVID-related customer demand, regulatory and reimbursement developments, and customer concentration.